These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 28504901)

  • 1. Tale of Two Erythropoiesis-Stimulating Agents: Utilization, Dosing, Litigation, and Costs of Darbepoetin and Epoetin Among South Carolina Medicaid-Covered Patients With Cancer and Chemotherapy-Induced Anemia.
    Noxon V; Knopf KB; Norris LB; Chen B; Yang YT; Qureshi ZP; Hrushesky W; Lebby AA; Schooley B; Hikmet N; Dickson M; Thamer M; Cotter D; Yarnold PR; Bennett CL
    J Oncol Pract; 2017 Jun; 13(6):e562-e573. PubMed ID: 28504901
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Economic evaluation of weekly epoetin alfa versus biweekly darbepoetin alfa for chemotherapy-induced anaemia: evidence from a 16-week randomised trial.
    Reed SD; Radeva JI; Daniel DB; Mody SH; Forlenza JB; McKenzie RS; Schulman KA
    Pharmacoeconomics; 2006; 24(5):479-94. PubMed ID: 16706573
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of erythropoiesis-stimulating agents among chemotherapy patients with hemoglobin exceeding 12 grams per deciliter.
    Nordstrom BL; Luo W; Fraeman K; Whyte JL; Nordyke RJ
    J Manag Care Pharm; 2008; 14(9):858-69. PubMed ID: 19006442
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A multicenter retrospective cohort study of practice patterns and clinical outcomes of the use of darbepoetin alfa and epoetin alfa for chemotherapy-induced anemia.
    Schwartzberg L; Shiffman R; Tomita D; Stolshek B; Rossi G; Adamson R
    Clin Ther; 2003 Nov; 25(11):2781-96. PubMed ID: 14693304
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness of darbepoetin alfa versus epoetin alfa in patients with chemotherapy-induced anemia treated in clinical practice.
    Patton J; Reeves T; Wallace J
    Oncologist; 2004; 9(4):451-8. PubMed ID: 15266098
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epoetin alfa versus darbepoetin alfa in chemotherapy-related anemia.
    Cersosimo RJ; Jacobson DR
    Ann Pharmacother; 2006 Jan; 40(1):58-65; quiz 169-70. PubMed ID: 16332942
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dose efficiency of erythropoiesis-stimulating agents for the treatment of patients with chemotherapy-induced anemia: a systematic review.
    Forbes CA; Worthy G; Harker J; Kleijnen J; Kutikova L; Zelek L; Van Belle S
    Clin Ther; 2014 Apr; 36(4):594-610. PubMed ID: 24656152
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epoetin alfa and darbepoetin alfa for the treatment of chemotherapy-related anemia in cancer patients in Sweden: comparative analysis of drug utilization, costs, and hematologic response.
    Persson U; Borg S; Jansson S; Ekman T; Franksson L; Friesland S; Larsson AM
    Adv Ther; 2005; 22(3):208-24. PubMed ID: 16236682
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The impact of methodological approach on cost findings in comparison of epoetin alfa with darbepoetin alfa.
    Song X; Long SR; Marder WD; Sullivan SD; Kallich J
    Ann Pharmacother; 2009 Jul; 43(7):1203-10. PubMed ID: 19584392
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Budget impact analysis of darbepoetin alfa every 3 weeks versus epoetin alfa every week for the treatment of chemotherapy-induced anaemia from a US payer's perspective.
    Rubin RJ; Glaspy JA; Adams JL; Mafilios MS; Wang SM; Viswanathan HN; Kallich JD
    J Med Econ; 2008; 11(2):199-213. PubMed ID: 19450080
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness of darbepoetin alfa versus epoetin alfa for the treatment of chemotherapy induced anemia in patients with gynecologic malignancies.
    Case AS; Rocconi RP; Kilgore LC; Barnes MN
    Gynecol Oncol; 2006 Jun; 101(3):499-502. PubMed ID: 16406064
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outcomes of erythropoiesis-stimulating agents in cancer patients with chemotherapy-induced anemia.
    Pashos CL; Larholt K; Fraser KA; McKenzie RS; Senbetta M; Piech CT
    Support Care Cancer; 2012 Jan; 20(1):159-65. PubMed ID: 21359879
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use and cost of erythropoiesis-stimulating agents in patients with cancer.
    Daniel G; Hurley D; Whyte JL; Willey V; Wilson M; Kallich J
    Curr Med Res Opin; 2009 Jul; 25(7):1775-84. PubMed ID: 19505205
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use and prescribing patterns for erythropoiesis-stimulating agents in inpatient and outpatient hospital settings.
    Siegel J; Jorgenson J; Johnson PE; Brophy DF; Comstock T; Feng A; Audhya P
    Am J Health Syst Pharm; 2008 Sep; 65(18):1711-9. PubMed ID: 18768997
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Utilization of darbepoetin alfa and epoetin alfa for chemotherapy-induced anemia.
    Herrington JD; Davidson SL; Tomita DK; Green L; Smith RE; Boccia RV
    Am J Health Syst Pharm; 2005 Jan; 62(1):54-62. PubMed ID: 15658073
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of chemotherapy-induced anemia in breast cancer: results of a randomized controlled trial of darbepoetin alfa 200 microg every 2 weeks versus epoetin alfa 40,000 U weekly.
    Senecal FM; Yee L; Gabrail N; Charu V; Tomita D; Rossi G; Schwartzberg L
    Clin Breast Cancer; 2005 Dec; 6(5):446-54. PubMed ID: 16381629
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical benefits and risks associated with epoetin and darbepoetin in patients with chemotherapy-induced anemia: a systematic review of the literature.
    Ross SD; Allen IE; Henry DH; Seaman C; Sercus B; Goodnough LT
    Clin Ther; 2006 Jun; 28(6):801-31. PubMed ID: 16860166
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized comparison of every-2-week darbepoetin alfa and weekly epoetin alfa for the treatment of chemotherapy-induced anemia in patients with breast, lung, or gynecologic cancer.
    Schwartzberg LS; Yee LK; Senecal FM; Charu V; Tomita D; Wallace J; Rossi G
    Oncologist; 2004; 9(6):696-707. PubMed ID: 15561813
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Switch From Epoetin Beta to Darbepoetin Alfa Treatment of Anemia in Taiwanese Hemodialysis Patients: Dose Equivalence by Hemoglobin Stratification.
    Liao SC; Hung CC; Lee CT; Lee CH; Lee CC; Lin CL; Sun CY; Cheng BC; Yang CC; Wu CH; Chen JB
    Ther Apher Dial; 2016 Aug; 20(4):400-7. PubMed ID: 27060362
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of darbepoetin alfa and epoetin alfa in clinical practice in patients with cancer-related anemia.
    Berger A; Edelsberg J; Kallich J; Oster G
    Clin Ther; 2008 Jan; 30(1):206-18. PubMed ID: 18343258
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.